Lymphatic Metastasis Predicts Better Response to Nivolumab in Recurrent or Metastatic Gastric Cancer: Insights from Tumor-Draining Lymph Node Immunity and Long-Term Outcomes
{{output}}
Background: Nivolumab has become an essential therapeutic agent for patients with advanced or recurrent gastric cancer. However, the impact of metastatic patterns on its clinical efficacy has not been fully elucidated. This study... ...
